News | September 3, 2024

Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis -413 patients enrolled in PEAK Phase 3 GIST trial, exceeding enrollment target; top-line...